N/A N=216 Improving Communication During a Pandemic Flu Outbreak
Healthy
Primary: Change in Intentions to Take Antivirals for Pandemic Flu — 8.29; 8.16; 8.23; 8.35 score on a scale — p=>.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=385 Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
Influenza · Influenza Vaccines
Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer
Phase 3 N=844 Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules
Influenza
Primary: Number of Subjects Boosted at Month 12 With Haemagglutinin-inhibition (HI) Antibody Concentrations Above the Cut-off Value — 178 Participants
N/A N=178 Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza
Influenza Virus Infection Transmission in Humans
Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number
N/A N=1,918 FluSAFE: Flu SMS Alerts to Freeze Exposure
Influenza · Acute Respiratory Infection · Influenza-like Illness
Primary: Number of Laboratory-confirmed Influenza Infections — .22; .14 infections
Phase 4 N=29,255 Control of Epidemic Influenza Through a School-based Influenza Vaccination Program
Influenza
Primary: MAARI Rate During the Epidemic Period (2007-2008) — 12503; 18998 Number of MAARI
Phase 3 N=5,071 Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above
Influenza
Primary: Number of Subjects With Solicited Local Symptoms — 212; 16; 39; 3 Participants
N/A N=544 Feasibility of Cocooning Immunization Strategy With Influenza Vaccine
Influenza
Primary: Influenza Vaccine Coverage (Percent) for New Mothers of Newborns — 70; 64 Percentage of Participants
N/A N=87,665 From Innovation to Solutions: Childhood Influenza Vaccination Planning
Influenza
Primary: Primary Outcome — 26432; 19352 participants vaccinated out of all — p=<0.05
N/A N=6,525 Surveillance for Adverse Events Following Pandemic H1N1 Immunization
Novel Influenza A/H1N1
Primary: Number of Participants Who Had Experienced a New Health Problem or the Worsening of an Existing Health Condition That Resulted in a Medical Consultation. — 234…
N/A N=7,645 Surveillance for Adverse Events Following Influenza Immunization
Influenza · Vaccines Adverse Reaction
Primary: Number of Participants Who Had Experienced a New Health Problem or the Worsening of an Existing Health Condition That Resulted in a Medical Consultation — 153 participants
N/A N=1,839 Prevalence, Strain Circulation and Disease Burden Study of Seasonal Influenza A and B in Panama, Selected Countries of Central America and the Caribbean From the Year 2010 to 2015
Influenza, Human
Primary: Number of Seasonal Influenza A and /or B Cases by Age Group, in Panama (Using the Data Reported Via National Influenza Surveillance Program) — 448; 120; 123; 47…
Phase 4 N=165 Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders
Plasma Cell Neoplasm
Primary: Seroprotection Based on Hemagglutination Antibody Inhibition (HAI) — 32; 22 Participants
Phase 3 N=64 Zanamivir Versus Trivalent Split Virus Influenza Vaccine
Influenza
Primary: Number of Laboratory Confirmed Influenza Infections — 2; 1 infections — p=0.25
Phase 4 N=18 Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 0; 17 Participants
Phase 4 N=481 Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle
Influenza · Respiratory Viral Infection
Primary: Initiate Antiviral Therapy Within 48 Hours of Symptom Onset — 8 Participants
N/A N=30,537 TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child Populations
Influenza
Primary: Influenza Immunization: Pediatric — 43.6; 39.9 % participant vaccinated with influenza
Phase 2 N=405 Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects
Pandemic · Avian Influenza
Primary: Number Subjects Who Responded to Two or Three Vaccinations of the MF59-H5N1 Influenza Vaccine — 0; 1; 0; 2 Subjects
Phase 4 N=22 Special Access Program IMVAMUNE®
Vaccination
Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects
Phase 2 N=59 The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
Influenza
Primary: Mean Area Under the Viral Load-Time Curve (VL-AUC) After Influenza Viral Challenge — 16.09; 10.70 log[10] copies/milliliter (mL)*hour — p=0.0390
Phase 2 N=326 High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Influenza · Avian Influenza · Severe Influenza
Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42
N/A N=4,561 Influenza Resistance Information Study
Influenza
Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants
Phase 1 N=45 Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine
Influenza
Primary: Safety - Serious Adverse Event — 0; 0; 0 SAEs
Phase 2 N=341 Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
Influenza
Primary: The Difference in Seroconversion/Immunogenicity Between rHA Formulated in an oil-in- Water Adjuvant (SE) Compared to a rHA Antigen Alone. — 83; 70; 9; 76 percentage of…
Phase 3 N=468 Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza?
Influenza
Primary: Number of pH1N1 Influenza Infections as Diagnosed by PCR From Mid-turbinate Swab — 2; 4 participants — p=0.685
Phase 2 N=66 Study Examining PrEP-001 in Healthy Subjects
Influenza A H3N2
Primary: Primary Efficacy Endpoint: The Area Under the Curve (AUC) of Total Symptom Score From Day 1 (Post Viral Challenge) to Day 8 (Quarantine Discharge). — 17956.5; 4502.6…
Phase 2 N=48 Influenza A 2009 H1N1 Challenge Study in Healthy Adults
Influenza
Primary: Percent MMID — 0; 0; 20; 47 percentage of participants
Phase 2 N=98 Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
Influenza A · Influenza B
Primary: Time to Normalization of Respiratory Status (Primary Efficacy Population) — 7; 28 days — p=0.069
N/A N=171,705 Prophylactic Efficacy of Relenza Against Influenza A and B
Pulmonary Disease, Chronic Obstructive · Bronchospasm · Influenza, Human
Primary: Number of Patients With Influenza — 3; 10; 2539; 93 patients
Phase 2 N=392 Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
Influenza
Primary: Evaluation of Immunogenicity Measured by Seroconversion Rates of PanBlok With and Without Adjuvant Compared to Placebo in Healthy Adults 18-49 Years of Age. — 0; 32; 15…